The Epoxy Group of pramanicin is required for the optimal endothelium-dependent relaxation of rat aorta

Journal of Pharmacological Sciences

Volumn 92, Issue 3, 2003, Pages 203-208

  Kwan, Chiu Yin ^a   Zhang, Wen Bo ^a   Miller, Joanna ^a   Harrison, Paul H M ^a   Kassan, Salina ^a   Liscombe, David ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Antifungal agent; Endothelial cell; Nitric oxide; Rat aorta; Smooth muscle cell

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIFUNGAL AGENT; CARBACHOL; EPOXIDE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; POTASSIUM CHLORIDE; PRAMANICIN; PRAMANICIN A; PRAMANICIN B; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; AORTA; ARTERY CONSTRICTION; ARTICLE; CELL FUNCTION; CHEMICAL BOND; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENDOTHELIUM CELL; INCUBATION TIME; INHIBITION KINETICS; LONG TERM CARE; MALE; NONHUMAN; RAT; STRUCTURE ANALYSIS; VASCULAR ENDOTHELIUM;

EID: 0042565988     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.92.203     Document Type: Article

References (15)

1. Schwartz RE, Helms RG, Bolessa EA, et al. Pramanicin, a novel antimicrobial agent from a fungal fermentation. Tetrahedron. 1994;50:1675-1686.
2. Harrison PHM, Hughes DW, Riddoch RW. The biosynthesis of pramanicin: Origin of the carbon skeleton. Chem Commun. 1998;273-274.
3. Kwan CY, Harrison PHM, Duspara PA, Daniel EE. Vaso-relaxant effects of pramanicin, an anti-fungal agent: Selective action on endothelial cells. Jpn J Pharmacol. 2001;85:234-240.
4. Gross SS, Wolin MS. Nitric oxide: Pathophysiological mechanisms. Ann Rev Physiol. 1995;57:737-769.
5. 2+ and cell death in cultured vascular endothelial cells. Vasc Pharmacol. 2003;40:35-42.
6. 2+ of aortic smooth muscle in endotoxin-treated rats: NO-dependent and -independent in vitro mechanisms. Res Commun Mol Pathol Pharmacol. 1996;92:275-284.
7. 2+ in EDRF release in rat aorta. J Vasc Res. 1994;31:18-24.
8. Duspara P, Jenkins SI, Hughes DW, Harrison PHM. The biosynthesis of pramanicin in Stagonospora sp. ATCC 74235: A modified acyltetramic acid. J Chem Soc Perkin Trans. 2000;1:4390-4402.
9. 2+ ATPase in rat skeletal muscle sarcoplasmic reticulum vesicles. Biochem Pharmacol. 1998;37:978-981.
10. 2+ transport by cyclopiazonic acid and thapsigargin in smooth muscle microsomes. Can J Physiol Pharmacol. 1996;74:182-192.
11. 2+-pump inhibitor of rat aortic muscle: A functional study. Acta Pharmacol Sin. 1991;12;53-58.
12. Kwan CY, Kwan TK. Effects of Panax notoginseng saponins on vascular endothelial cells in vitro. Acta Pharmacol Sin. 2000;21:1101-1105.
13. Tran QK, Watanabe H, Le HY, et al. Insulin inhibits coronary endothelial cell calcium entry and coronary artery relaxation. J Cardiovasc Pharmacol. 2001;38:885-892.
14. Lytton J, Westlin M, Hanley MR. Thapsigargin inhibits the sarcoplasmic or endoplasmic reticulum Ca-ATPase family of calcium pumps. J Biol Chem. 1991;266:17067-17071.
15. 2+ pump ATPases in porcine aorta. Gen Pharmacol. 2000;34:211-220.